Sign In
Last checked at 
5 May 2011 07:00
ο»Ώ
For immediate release | 5 May 2011 |
Β
Β
Futura Medical plc
("Futura" or "the Company")
Β
AGM Statement
Β
Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, will hold its Annual General Meeting in London later today.
Β
At the meeting, Dr William Potter, the Company's Chairman, will make the following statement:
Β
"The current financial year has started well for Futura, and we look forward to the commercial launch of PET500 and to the award of the CE mark for CSD500.
Β
"Futura is on the threshold of becoming a company that benefits from significant royalty income. We look to the future with confidence."
Β
For any further information please contact:
Β
Futura Medical plc | Β |
James Barder, Chief Executive Β | Tel: +44 (0)1483 685 670 |
mail to: james.barder@futuramedical.com | www.futuramedical.com |
Β | Β |
Β Nomura Code Securities Limited | Β |
Phil Walker / Giles Balleny | Tel:+44 (0)20 7776 1200 |
Β Β | Β |
For media enquiries please contact: | Β |
Β | Β |
Buchanan Communications | Β |
Mark Court / Jessica Fontaine | Tel: +44 (0)20 7466 5000 |
Β
Β
Notes to Editors
Β
Futura Medical plc
Β
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Β
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com
Follow the stocks
